title: [Efficacy and adverse reactions of the TNFalpha inhibitor infliximab in rheumatoid arthritis].
abstract: Abundant evidence of infliximab (tumor necrosis factor inhibitor) has been collected in rheumatoid arthritis. Infliximab is effective not only for resolving the clinical symptoms, but also for preventing joint destruction. It has also been reported that discontinuation of this drug is possible after attaining low disease activity. This is one of the characteristics of infliximab. However, patients should be adequately cautioned against the development of adverse reactions, such as infections. It is essential to carefully select patients eligible for treatment with infliximab based on the guidelines established by the Japan College of Rheumatology, and adverse reactions to the drug should be prevented or detected early and treated promptly.
authors: Department of Orthopedic Surgery, Yamaguchi University Graduate School of Medicine.
authors: Takashi
authors: T
authors: Imagama
authors: Toshihiko
authors: T
authors: Taguchi
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D006801:Humans; D000069285:Infliximab; D008727:Methotrexate / Q000627:therapeutic use; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D008727:Methotrexate